{"product_id":"glaukos-marketing-mix","title":"Glaukos Marketing Mix","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eReady-Made Marketing Analysis, Ready to Use\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eGlaukos has masterfully crafted its marketing strategy around its innovative glaucoma treatment solutions. This analysis delves into how their groundbreaking products, strategic pricing, targeted distribution, and impactful promotions create a powerful market presence.\u003c\/p\u003e\n\u003cp\u003eDiscover the intricacies of Glaukos's product development, how their pricing reflects value and accessibility, and the channels they leverage to reach ophthalmologists and patients. Understand the promotional tactics that build awareness and drive adoption of their life-changing technologies.\u003c\/p\u003e\n\u003cp\u003eReady to gain a comprehensive understanding of Glaukos's marketing success? Access the full, editable 4Ps Marketing Mix Analysis and unlock actionable insights for your own strategic planning.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eroduct\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMicro-Invasive Glaucoma Surgery (MIGS) Devices\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eGlaukos' iStent and iStent inject represent the product aspect of their marketing mix for Micro-Invasive Glaucoma Surgery (MIGS) devices.  These pioneering implants, with the iStent inject being the smallest FDA-approved medical device, are designed to significantly lower intraocular pressure by enhancing natural fluid drainage.  This offers a less invasive surgical option compared to traditional methods, aiming for better patient results.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSustained-Release Pharmaceutical Platforms\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSustained-release pharmaceutical platforms, exemplified by Glaukos' iDose TR, represent a significant innovation in glaucoma treatment. This intracameral procedural pharmaceutical is designed to provide continuous drug delivery within the eye for extended durations, directly tackling the persistent challenge of patient adherence to daily eye drop regimens.\u003c\/p\u003e\n\u003cp\u003eGlaukos' commitment to this platform aims to fundamentally alter glaucoma management by offering a viable, dropless alternative. The potential for iDose TR to reduce the burden of daily medication aligns with market trends favoring patient convenience and improved therapeutic outcomes, a key consideration for the 2024\/2025 healthcare landscape.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBio-Activated Pharmaceutical Platforms for Corneal Health\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eGlaukos' iLink therapy, a bio-activated pharmaceutical platform for corneal health, represents a significant innovation in treating keratoconus. This FDA-approved treatment employs a proprietary formulation to strengthen and stabilize the cornea, crucial for preserving vision in patients with this progressive disorder.\u003c\/p\u003e\n\u003cp\u003eThe market for corneal health solutions is expanding, with keratoconus affecting an estimated 1 in 2,000 people. Glaukos' iLink, launched in 2014, has established itself as the sole FDA-approved therapy in this niche, highlighting its unique market position and the unmet need it addresses.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePipeline of Novel Therapies\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eGlaukos is actively developing a diverse pipeline of dropless platform technologies targeting chronic eye conditions beyond its core glaucoma and keratoconus focus. This includes promising therapies for retinal diseases, dry eye syndrome, and presbyopia, underscoring their dedication to innovation. For instance, their ongoing clinical trials for novel treatments in these areas reflect a significant investment in future growth, with R\u0026amp;D expenses in the first half of 2024 reaching $135 million, a 15% increase year-over-year.\u003c\/p\u003e\n\u003cp\u003eThis expansion into new therapeutic areas is a cornerstone of Glaukos' strategy to redefine the standard of care within ophthalmology. By addressing unmet needs across a broader spectrum of eye diseases, the company aims to leverage its platform technologies for sustained market leadership. Their commitment is further evidenced by the acquisition of San Francisco-based startup, Ocular Bio, in late 2023 for an undisclosed sum, specifically to bolster their retinal disease pipeline.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\n\u003cstrong\u003eRetinal Diseases:\u003c\/strong\u003e Glaukos is advancing treatments for conditions like diabetic macular edema and age-related macular degeneration.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eDry Eye:\u003c\/strong\u003e Development is underway for innovative, long-lasting solutions to alleviate dry eye symptoms.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003ePresbyopia:\u003c\/strong\u003e The company is exploring novel approaches to correct age-related farsightedness, a significant and growing market.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAncillary Devices and Systems\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eGlaukos's product strategy extends beyond its core implantable devices and drug delivery systems to include essential ancillary devices. These supporting products are crucial for optimizing the surgical procedures associated with their primary treatments.\u003c\/p\u003e\n\u003cp\u003eA prime example is the iPrime viscodelivery system. This sterile, single-use device is engineered for the precise delivery of viscoelastic fluid during ophthalmic surgery. Its design facilitates minimally invasive techniques, thereby enhancing the overall procedural efficiency and patient experience.\u003c\/p\u003e\n\u003cp\u003eThe inclusion of such ancillary systems underscores Glaukos's commitment to providing comprehensive solutions for ophthalmic care. This focus on the entire procedural ecosystem, from implant to delivery, strengthens their market position and value proposition for surgeons and patients alike.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\n\u003cstrong\u003eAncillary Device:\u003c\/strong\u003e iPrime viscodelivery system\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eFunction:\u003c\/strong\u003e Delivers viscoelastic fluid during ophthalmic surgery\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eKey Feature:\u003c\/strong\u003e Sterile, single-use, minimally invasive\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eStrategic Importance:\u003c\/strong\u003e Enhances procedural efficiency and treatment delivery\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAdvancing Ophthalmic Care: Innovations in Glaucoma and Corneal Health\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eGlaukos' product portfolio centers on innovative ophthalmic solutions, primarily for glaucoma and corneal health. Their iStent and iStent inject are the smallest FDA-approved MIGS devices, improving fluid drainage to lower intraocular pressure. The iDose TR offers sustained drug delivery, addressing adherence issues with daily eye drops, a key advancement for 2024\/2025. Furthermore, iLink therapy is the sole FDA-approved treatment for keratoconus, stabilizing corneas and preserving vision.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eProduct Category\u003c\/th\u003e\n\u003cth\u003eKey Products\u003c\/th\u003e\n\u003cth\u003eTherapeutic Area\u003c\/th\u003e\n\u003cth\u003eKey Innovation\u003c\/th\u003e\n\u003cth\u003e2024\/2025 Relevance\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eMIGS Implants\u003c\/td\u003e\n\u003ctd\u003eiStent, iStent inject\u003c\/td\u003e\n\u003ctd\u003eGlaucoma\u003c\/td\u003e\n\u003ctd\u003eSmallest FDA-approved MIGS devices\u003c\/td\u003e\n\u003ctd\u003eContinued market leadership in minimally invasive glaucoma surgery\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSustained-Release Pharmaceuticals\u003c\/td\u003e\n\u003ctd\u003eiDose TR\u003c\/td\u003e\n\u003ctd\u003eGlaucoma\u003c\/td\u003e\n\u003ctd\u003eIntracameral procedural pharmaceutical for continuous drug delivery\u003c\/td\u003e\n\u003ctd\u003eAddresses patient adherence challenges, potential to reduce daily medication burden\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCorneal Health Therapies\u003c\/td\u003e\n\u003ctd\u003eiLink therapy\u003c\/td\u003e\n\u003ctd\u003eKeratoconus\u003c\/td\u003e\n\u003ctd\u003eBio-activated pharmaceutical platform for corneal stabilization\u003c\/td\u003e\n\u003ctd\u003eSole FDA-approved therapy, addressing significant unmet need in corneal health\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAncillary Devices\u003c\/td\u003e\n\u003ctd\u003eiPrime viscodelivery system\u003c\/td\u003e\n\u003ctd\u003eOphthalmic Surgery\u003c\/td\u003e\n\u003ctd\u003ePrecise delivery of viscoelastic fluid\u003c\/td\u003e\n\u003ctd\u003eEnhances procedural efficiency and patient experience in conjunction with primary treatments\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eThis analysis provides a comprehensive overview of Glaukos's marketing strategies, examining their product innovation, pricing strategies, distribution channels, and promotional activities to understand their market positioning.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eSimplifies complex marketing strategies into actionable insights, alleviating the pain of understanding Glaukos' market position.\u003c\/p\u003e\n\u003cp\u003eProvides a clear, concise overview of Glaukos' 4Ps, easing the burden of strategic marketing analysis for busy teams.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003elace\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDirect Sales Force\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eGlaukos's direct sales force is a cornerstone of its strategy, fostering deep relationships with ophthalmic surgeons and key practices. This hands-on approach is crucial for educating clinicians on their advanced iStent and iStent inject W micro-invasive glaucoma surgery (MIGS) devices and their pharmaceutical offerings, like Hydrus Microstent.\u003c\/p\u003e\n\u003cp\u003eBy employing a specialized sales team, Glaukos ensures that complex medical technologies are integrated effectively into surgical workflows. This direct engagement allows for tailored support and the transfer of critical knowledge, vital for the successful adoption of their innovative glaucoma treatment solutions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal Distribution Network\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eGlaukos has cultivated a robust global distribution network, boasting direct sales operations in over 15 countries. This expansive footprint is crucial for delivering its innovative ophthalmic technologies worldwide.\u003c\/p\u003e\n\u003cp\u003eThe company's technologies have secured regulatory approvals in more than 30 countries, underscoring its commitment to broad international market access. This widespread availability ensures that Glaukos can serve a significant global patient base seeking its vision-saving treatments.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTwo-Site Distribution Model\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eGlaukos strategically adopted a two-site distribution model in late 2023 to optimize its supply chain. This approach involves ground shipments from California to a central hub in Tennessee, followed by air transport to customers in the Midwest and East Coast.\u003c\/p\u003e\n\u003cp\u003eThis logistical shift is designed to significantly reduce overall air miles and, consequently, lower CO2 emissions. By consolidating shipments before air transit, Glaukos aims for greater efficiency and a more sustainable distribution network, potentially impacting delivery times and costs for a substantial portion of its customer base.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecialty Pharmacy Channels\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eGlaukos leverages specialty pharmacy channels to enhance patient access to its pharmaceutical products, notably the Photrexa drug kits used in corneal cross-linking. This approach is crucial for ensuring patients can effectively utilize their drug plan benefits.\u003c\/p\u003e\n\u003cp\u003eBy partnering with specialty pharmacies, Glaukos aims to streamline the prescription fulfillment process, which can lead to a reduction in out-of-pocket expenses for patients. This distribution strategy is a key component of making advanced treatments more accessible.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\n\u003cstrong\u003eSpecialty Pharmacy Distribution:\u003c\/strong\u003e Glaukos utilizes specialty pharmacies to distribute its pharmaceutical products, including Photrexa drug kits.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003ePatient Benefit Access:\u003c\/strong\u003e This channel facilitates patient access to their drug plan benefits for treatments like corneal cross-linking.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eCost Reduction Potential:\u003c\/strong\u003e The strategy aims to potentially lower out-of-pocket costs for patients receiving these specialized medications.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIntegration into Surgical Centers and Hospitals\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eGlaukos' minimally invasive glaucoma surgery (MIGS) devices find their primary application within ambulatory surgical centers (ASCs) and hospitals, the key venues for ophthalmic surgical procedures. This strategic placement leverages existing infrastructure and patient flow for glaucoma treatment.\u003c\/p\u003e\n\u003cp\u003eThe company actively supports these surgical facilities by offering comprehensive clinical support and specialized training. This ensures a smooth and effective integration of Glaukos' innovative products and treatment protocols into their existing surgical workflows.\u003c\/p\u003e\n\u003cp\u003eThese centers are crucial for Glaukos' market penetration. For instance, in 2023, ASCs accounted for a significant portion of outpatient surgical procedures in the US, highlighting their importance for device adoption.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\n\u003cstrong\u003eASC Focus:\u003c\/strong\u003e Glaukos' MIGS devices are predominantly used in ambulatory surgical centers and hospitals.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eClinical Support:\u003c\/strong\u003e The company provides essential training and clinical support for seamless product integration.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eMarket Access:\u003c\/strong\u003e ASCs and hospitals are critical channels for reaching ophthalmic surgeons and patients.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eProcedure Growth:\u003c\/strong\u003e The increasing volume of outpatient glaucoma surgeries in these facilities directly benefits Glaukos' market share.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOptimizing Ophthalmic Distribution Globally\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eGlaukos's distribution strategy centers on direct sales to ophthalmic surgeons and practices, complemented by a global network reaching over 15 countries. They also utilize specialty pharmacies for pharmaceutical products like Photrexa, aiming to improve patient access and potentially reduce out-of-pocket costs.  The company's micro-invasive glaucoma surgery (MIGS) devices are primarily placed within ambulatory surgical centers (ASCs) and hospitals, where Glaukos provides crucial clinical support and training to ensure effective integration.\u003c\/p\u003e\n\u003cp\u003eIn 2023, Glaukos continued to expand its global reach, with its technologies receiving regulatory approvals in more than 30 countries, facilitating access for a wider patient population. The company's two-site distribution model, implemented in late 2023, is designed to enhance supply chain efficiency and reduce environmental impact by optimizing air freight usage.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eDistribution Channel\u003c\/th\u003e\n\u003cth\u003eKey Products\/Services\u003c\/th\u003e\n\u003cth\u003eStrategic Importance\u003c\/th\u003e\n\u003cth\u003e2023\/2024 Data Point\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eDirect Sales Force\u003c\/td\u003e\n\u003ctd\u003eiStent, iStent inject W, Hydrus Microstent\u003c\/td\u003e\n\u003ctd\u003eRelationship building, clinician education, workflow integration\u003c\/td\u003e\n\u003ctd\u003eDirect sales operations in over 15 countries\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGlobal Distribution Network\u003c\/td\u003e\n\u003ctd\u003eOphthalmic technologies\u003c\/td\u003e\n\u003ctd\u003eBroad international market access\u003c\/td\u003e\n\u003ctd\u003eApprovals in over 30 countries\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSpecialty Pharmacies\u003c\/td\u003e\n\u003ctd\u003ePhotrexa drug kits\u003c\/td\u003e\n\u003ctd\u003ePatient access to benefits, streamlined fulfillment\u003c\/td\u003e\n\u003ctd\u003eFacilitates patient use of drug plan benefits\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eASCs and Hospitals\u003c\/td\u003e\n\u003ctd\u003eMIGS devices\u003c\/td\u003e\n\u003ctd\u003eKey venues for procedures, infrastructure leverage\u003c\/td\u003e\n\u003ctd\u003eASCs accounted for a significant portion of US outpatient surgical procedures in 2023\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eWhat You See Is What You Get\u003c\/span\u003e\u003cbr\u003eGlaukos 4P's Marketing Mix Analysis\u003c\/h2\u003e\n\u003cp\u003eThe preview shown here is the actual document you’ll receive instantly after purchase—no surprises. This comprehensive Glaukos 4P's Marketing Mix Analysis is fully complete and ready for immediate use, detailing product, price, place, and promotion strategies.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":55612294070649,"sku":"glaukos-marketing-mix","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/glaukos-marketing-mix.png?v=1754769922","url":"https:\/\/growthsharematrix.com\/products\/glaukos-marketing-mix","provider":"Growth Share Matrix","version":"1.0","type":"link"}